Your browser doesn't support javascript.
loading
Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne, Rebecca; Balu, Sanjeev; Guérin, Annie; Bungay, Rebecca; Sin, Roxana; Paul, Mary Lisha.
Affiliation
  • Burne R; Analysis Group, Montréal, Canada.
  • Balu S; Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Guérin A; Analysis Group, Montréal, Canada.
  • Bungay R; Analysis Group, Montréal, Canada.
  • Sin R; Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Paul ML; Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
J Med Econ ; 24(1): 806-815, 2021.
Article in En | MEDLINE | ID: mdl-34098827
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Implementation_research Limits: Aged / Female / Humans Country/Region as subject: America do norte Language: En Journal: J Med Econ Journal subject: SERVICOS DE SAUDE Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Implementation_research Limits: Aged / Female / Humans Country/Region as subject: America do norte Language: En Journal: J Med Econ Journal subject: SERVICOS DE SAUDE Year: 2021 Document type: Article Affiliation country: Country of publication: